Srdan Verstovsek, MD, PhD, is a Medical Oncologist and Professor at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr Verstovsek completed his medical degree and his PhD at the University of Zagreb, Zagreb, Croatia. Dr Verstovsek then moved to Buffalo, NY, to complete his internal medicine residency at the State University of New York, NY, which was followed by a fellowship in oncology-hematology at the University of Texas MD Anderson Cancer Center, Houston, TX.
Speaking on myeloproliferative neoplasm therapeutics
Dr Verstovsek’s main research interests lie in developing novel therapies for the treatment of myeloproliferative neoplasms (MPNs), in particular for myelofibrosis. He has led over 60 clinical trials – both early and advanced phase trials – including trials of ruxolitinib, which became the first JAK inhibitor to receive FDA approval for the treatment of patients with myelofibrosis in 2011.